Key Developments: Orexigen Therapeutics Inc (OREX.O)

OREX.O on Nasdaq

4.39USD
24 Oct 2014
Price Change (% chg)

$0.01 (+0.23%)
Prev Close
$4.38
Open
$4.40
Day's High
$4.42
Day's Low
$4.30
Volume
2,043,814
Avg. Vol
4,178,982
52-wk High
$7.82
52-wk Low
$3.11

Search Stocks

Latest Key Developments (Source: Significant Developments)

Takeda and Orexigen announce FDA approval of Contrave (naltrexone HCI and bupropion HCI) extended-release tablets for chronic weight management
Thursday, 11 Sep 2014 07:00am EDT 

Orexigen Therapeutics Inc and Takeda Pharmaceuticals U.S.A., Inc:U.S. FDA approves Contrave(naltrexone HCI and bupropion HCI) extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults.Effect of Contrave on cardiovascular morbidity and mortality has not been established.  Full Article

Orexigen Therapeutics Inc expands NB32 intellectual property portfolio with new U.S. Patent
Tuesday, 2 Sep 2014 08:00am EDT 

Orexigen Therapeutics Inc:Announced that U.S. Patent and Trademark Office (PTO) has issued patent related to NB32, Company's investigational medication being evaluated for weight loss.NB32 is fixed-dose combination of naltrexone sustained release and bupropion SR.Patent expires in 2024.Patent for treating insulin resistance using composition including naltrexone and bupropion.  Full Article

Orexigen Therapeutics Inc receives three month extension of FDA NB32 review
Wednesday, 11 Jun 2014 06:30am EDT 

Orexigen Therapeutics Inc:Says the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the company's investigational medication being evaluated for weight loss.The new Prescription Drug User Fee Act (PDUFA) action date has been set for Sept. 11, 2014.The FDA has indicated that the review extension is needed to reach agreement on the post-marketing obligation related to the previously agreed upon evaluation of cardiovascular (CV) outcomes for NB32.  Full Article

Orexigen Therapeutics Inc announces closing of its offering of $115 mln of convertible senior notes
Friday, 6 Dec 2013 10:45am EST 

Orexigen Therapeutics Inc:Says the closing of its offering of $115 mln aggregate principal amount of convertible senior notes due 2020.Says convertible senior notes also includes $15 mln aggregate principal amount of the Notes issued in connection with the exercise by the initial purchasers of their option to purchase additional Notes in full.Says the Notes were offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.Says the Notes bear interest semi-annually at a rate of 2.75 percent per year.Says the Notes will mature on Dec. 1, 2020, unless earlier repurchased or converted in accordance with their terms prior to such date.Says it estimates that the net proceeds from the offering will be about $110.5 million after deducting the initial purchasers' discounts and commissions and the estimated offering expenses payable by it.Says the company intends to use the net proceeds from the offering of the Notes for working capital and other general corporate purposes.  Full Article

Orexigen Therapeutics Inc announces offering of $100 mln of convertible senior notes
Monday, 2 Dec 2013 07:00am EST 

Orexigen Therapeutics Inc:Says it intends to offer $100 mln aggregate principal amount of convertible senior notes due 2020.Says it intends to use the net proceeds from the offering of the Notes for working capital and other general corporate purposes.  Full Article

Robbins Arroyo LLP Is Investigating Directors and Officers of Orexigen Therapeutics Inc
Monday, 12 Aug 2013 07:42pm EDT 

Robbins Arroyo LLP is investigating whether certain officers and directors of Orexigen Therapeutics Inc breached their fiduciary duties to shareholders. Orexigen focuses on the development of pharmaceutical product candidates for the treatment of obesity.  Full Article

The Law Firm of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Orexigen Therapeutics Inc
Tuesday, 7 May 2013 11:52am EDT 

Levi & Korsinsky, LLP announced that it is investigating Orexigen Therapeutics Inc and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.  Full Article

BUZZ-Orexigen Therapeutics Inc: Diet drug launched

** Drugmaker's shares up 20 pct at $4.88, biggest intra-day percentage jump in more than two years

Search Stocks